试验雷达 AI | ||
|---|---|---|
临床试验 NCT04320069 针对1型糖尿病目前已完成。请查看临床试验雷达卡片视图和 AI 发现工具了解所有详情，或在此提出任何问题。 | ||
一个试验符合筛选条件
卡片视图
Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study 25
临床试验详情主要以英语提供。然而，试验雷达 AI可以提供帮助！只需点击“试验详解”即可查看和讨论您选择的语言的试验信息。
临床试验NCT04320069是一项针对1型糖尿病的干预性研究试验，试验状态为已完成。试验开始于2020年6月9日，共计划招募25名患者。该研究由Insulet Corporation主导，已于2020年9月29日完成。试验数据来源于ClinicalTrials.gov，最后更新时间为2023年11月13日。
简要概括
Subjects will use the Omnipod Horizon™ System in Manual Mode in an outpatient setting for 14-days. Subjects will be trained to use the Manual Mode feature of the Omnipod Horizon™ System including how to use the bolus calculator using manual entry of blood glucose values or by using the CGM-informed bolus calculator.
详细描述
The study schedule consists of two outpatient phases:
- 7 days of Omnipod Horizon™ use in Manual Mode without a connected CGM using manual entry of BG values to deliver boluses (Phase 1) followed by;
- 7 days of Omnipod Horizon™ use in Manual Mode with a connected CGM using the CGM-informed bolus calculator to deliver boluses (Phase 2)
Following subject screening, system training and enrollment, subjects will com...
显示更多官方标题
Evaluating the Safety and Effectiveness of the Omnipod Horizon™ CGM-informed Bolus Calculator in Patients With Type 1 Diabetes
疾病
1型糖尿病出版物
关于此临床试验发表的科学文章和研究论文：其他研究标识符
- G200018
NCT编号
实际开始日期
2020-06-09
最近更新发布
2023-11-13
预计完成日期
2020-09-29
计划入组人数
25
研究类型
干预性研究
试验分期 (阶段)
不适用
试验状态
已完成
关键词
T1D
Omnipod
Omnipod
主要目的
治疗方法
分配方式
不适用
干预模型
单组试验
盲法
无（开放性试验）
试验组/干预措施
| 参与者组/试验组 | 干预措施/治疗方法 |
|---|---|
实验性Omnipod Horizon™ Automated Glucose Control System All subjects using the Omnipod Horizon™ Automated Glucose Control System in Manual Mode without a connected CGM for 7 days and with a connected CGM for 7 days. | Omnipod Horizon™ Automated Glucose Control System Omnipod Horizon™ Automated Glucose Control System use in Manual Mode |
主要终点
次要终点
| 结果指标 | 度量标准描述 | 时间框架 |
|---|---|---|
Percentage of Time <70 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period) |
Percentage of Time >180 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period) |
| 结果指标 | 度量标准描述 | 时间框架 |
|---|---|---|
Mean Glucose | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period) |
Percentage of Time <54 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period) |
Percentage of Time ≥ 250 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period) |
Percentage of Time ≥ 300 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period) |
Percentage of Time in Range 70-180 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1 (comparing the 4-hour post bolus period) |
Mean Glucose | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall |
Percentage of Time <54 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall |
Percentage of Time <70 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall |
Percentage of Time >180 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall |
Percentage of Time ≥ 250 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall |
Percentage of Time ≥ 300 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall |
Percentage of Time in Range 70-180 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall |
Percentage of Time in Range 70-140 mg/dL | Glucose metric from continuous glucose monitoring system (CGM) | Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall |
Standard Deviation | Glucose metric from study continuous glucose monitoring system (CGM)-measured glucose variability with the standard deviation (SD) | Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall |
Coefficient of Variation | Glucose metric from study continuous glucose monitoring system (CGM)-measured glucose variability with the coefficient of variation (CV) | Phase 2 compared to Phase 1, during the day (6AM up to 12AM), overnight (12AM up to 6AM), and overall |
资格标准
适龄参与研究
儿童, 成人, 老年人
最低年龄要求
2 Years
适龄性别
全部
- Age at time of consent/assent 2-70 years
- Subjects aged < 18 years must be living with parent/legal guardian
- Diagnosed with type 1 diabetes for at least 6 months. Diagnosis is based on investigator's clinical judgment
- Must be a current Omnipod user, or have used an Omnipod in the past
- Investigator has confidence that the subject, parent, or legal guardian, can successfully operate all study devices and can adhere to the protocol
- Willing to use only the following types of Insulin during the study: Humalog, Novolog, Admelog, or Apidra
- Must be willing to use the Omnipod Horizon™ in Manual Mode only and agree not to use Automated Mode functionality
- Must be willing to use the Omnipod Horizon™ bolus calculator without a connected CGM for the first 7-days of Manual Mode (Phase 1) while manually entering BG values to deliver boluses
- Must be willing to use the Omnipod Horizon™ bolus calculator with a connected CGM for the last 7-days of Manual Mode (Phase 2) using the CGM-informed bolus calculator to deliver boluses
- Willing to wear the system continuously throughout the study
- For subjects not currently enrolled in the Omnipod Horizon™ Pivotal Study (G190270), A1C <10%
- Must be willing to use the Dexcom App on the Omnipod Horizon™ PDM as the sole source of Dexcom data (except for the Dexcom Follow App)
- Able to read and speak English fluently (if subject is a young child then Caregiver must meet the criteria)
- Willing and able to sign the Informed Consent Form (ICF) and/or has a parent/guardian willing and able to sign the ICF. Assent will be obtained from subjects aged < 18 years per State requirements.
- For subjects aged 2-5.9 years of age, parents or trained caregivers agree to be physically present during the decision and delivery of insulin boluses for this age group, as well as agree to be available for glucose monitoring and treatment during the 4-hour post bolus period.
- A medical condition, which in the opinion of the investigator, would put the subject at an unacceptable safety risk
- History of severe hypoglycemia in the past 6 months
- History of DKA in the past 6 months, unrelated to an intercurrent illness or infusion set failure
- Plans to receive blood transfusion over the course of the study
- Currently diagnosed with anorexia nervosa or bulimia
- Acute or chronic kidney disease or currently on hemodialysis
- History of adrenal insufficiency
- Has taken oral or injectable steroids within the past 8 weeks or plans to take oral or injectable steroids during the study
- Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement
- Plans to use insulin other than U-100 insulin intended for use in the study device during the study
- Use of non-insulin anti-diabetic medication other than metformin (e.g. GLP1 agonist, SGLT2 inhibitor, DPP-4 inhibitor, pramlintide)
- Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the previous 12 months
- Clinical signs of hypothyroidism and hyperthyroidism
- Pregnant or lactating, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD or implant)
- Currently participating or plans to participate in another clinical study using an investigational drug or device other than Omnipod Horizon™. Subjects may be recruited from the Omnipod Horizon Pivotal Study (G190270) prior to their recommencement of the pivotal study after study pause.
- Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment
Insulet Corporation没有联系数据。
4 位于 1 个国家/地区的研究中心
California
Sansum Diabetes Research Institute, Santa Barbara, California, 93105, United States
Colorado
University of Colorado Denver, Denver, Colorado, 80045, United States
Georgia
Atlanta Diabetes, Atlanta, Georgia, 30318, United States
Virginia
University of Virginia, Charlottesville, Virginia, 22904, United States